Desang diabetes magazine diabetes news

NEWS

LAUNCH OF ONDUO SKIN JOB FOR

ISLET CELLS

A new way of holding insulin producing

islet cells inside the body has been

developed at the Royal Adelaide Hospital

in southern Australia, where doctors have

been trialling artificial skin, already used

globally in burns injuries, as a potential

site for the transplant of donor islet cells

used in the treatment of Type 1 diabetes.

Professor Toby Coates, Director of Kidney

and Pancreatic Islet Transplantation and

Associate Professor John Greenwood

AM, Director of the Burns Unit, are looking

into the effectiveness of transplanting

islet cells into artificial skin made of a

biodegradable material, rather than into

the liver. Coates says, "Traditionally we

transplant islet cells into the liver to help

treat Type 1 diabetes patients, however

the harsh and unforgiving environment of

the liver means that a large number of islet

cells die during the process.

"The key component of this research

is to modify and optimise the artificial

skin to create a new site to transplant

islet cells in people with Type 1 diabetes.

Transplanting islets into the artificial skin

instead of the liver is potentially a much

safer procedure, which will reduce the

total number of islets needed to transplant

for diabetes and allow more people

access to this life-changing transplant

procedure." JDRF has contributed nearly

$1 million to develop the new transplant

procedure. The doctors are hopeful the

treatment will be ready to be trialled on

people in the next two years.

Sanofi and Verily Life Sciences LLC,

(formerly Google Life Sciences), an

Alphabet company, today announced the

launch of Onduo, a joint venture created

through Sanofi and Verily's diabetesfocused collaboration.

Onduo's purpose is to help people

with diabetes live full, healthy lives by

developing comprehensive solutions that

combine devices, software, medicine, and

professional care to enable simple and

intelligent disease management. Under

the leadership of Onduo's CEO, Joshua

Riff, M.D., M.B.A. (pictured right), the

company will leverage Verily's experience

in miniaturized electronics, analytics, and

consumer software development, and

Sanofi's clinical expertise and experience

in bringing innovative treatments to people

living with diabetes.

Says Riff, "My experience as a

physician and in leading consumer health

initiatives has shown me the daily burden

of living with diabetes, from monitoring

food intake to testing glucose levels

to actively seeking medical care, the

challenges both on the physical and

mental well-being of a person living with

diabetes are incredibly difficult. We want

to develop solutions that allow people

living with diabetes to focus on the things

they love and enjoy in life by providing

tools to make dealing with their diabetes

less burdensome."

Initially, Onduo will focus on Type

2 diabetes, specifically on developing

solutions that could help people make

better decisions about their day to day

health, ranging from improved medication

management to improved habits and

goals. Over time, the company plans to

expand its focus to include the Type 1

diabetes, and eventually to people at risk

of developing diabetes with the goal of

helping them better prevent the onset of

the disease.

Onduo is in discussion with patient

advocacy groups such as Taking Control

of Your Diabetes (TCOYD) to provide input

on future product designs. Dr Steven

Edelman, founder and director of TCOYD

adds, "With Onduo, Sanofi and Verily are

bringing forward a platform that is novel

and critical in diabetes management.

Onduo is a company focused on the

improvement of health outcomes through

the marriage of technology and medicine.

Its information-based solutions align

well with TCOYD's mission to empower

people with diabetes and their loved

ones to effectively and easily take control

of diabetes. We welcome and support

Onduo's efforts and look forward to their

progress."

ISSUE 30

MAGAZINE

DESANG

PLUS • New Products • Groovy giveaways • News (for T1 and T2)

WE'RE NO

ANGELS

But business as usual is best for

diabetics at Christmas

MAKING

CARBS COUNT:

CHESTNUTS ROASTING

ON OPEN FIRES

Our magazine is free!

Sign up here! email address

Index

  1. Desang diabetes magazine diabetes information
  2. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  3. Desang diabetes magazine diabetes information, Sue Marshall
  4. Desang diabetes magazine diabetes news
  5. Desang diabetes magazine diabetes news
  6. Desang diabetes magazine diabetes news
  7. Accu-Chek Mobile blood glucose system
  8. Desang diabetes magazine diabetes diet
  9. Desang diabetes magazine diabetes diet
  10. diabetes kit, Ascensia Diabetes Care, Contour Next One
  11. diabetes kit, Ascensia Diabetes Care, Contour Next One
  12. The Accelerator Hypothesis, Professor Terry Wilkin, the ADAPT trial, cure for Type 1 diabetes
  13. The Accelerator Hypothesis, Professor Terry Wilkin, the ADAPT trial, cure for Type 1 diabetes
  14. The Accelerator Hypothesis, Professor Terry Wilkin, the ADAPT trial, cure for Type 1 diabetes
  15. Ascensia Contour Diabetes blood test meters
  16. The Accelerator Hypothesis, Professor Terry Wilkin, the ADAPT trial, cure for Type 1 diabetes
  17. The Accelerator Hypothesis, Professor Terry Wilkin, the ADAPT trial, cure for Type 1 diabetes
  18. The Accelerator Hypothesis, Professor Terry Wilkin, the ADAPT trial, cure for Type 1 diabetes
  19. Hid-In insulin pump belts, Leather ICE medical ID
  20. cured food, diabetes food, diabetes food news, desang diabetes magazine food news
  21. cured food, diabetes food, diabetes food news, desang diabetes magazine food news
  22. Making Carbs Count Aubergines
  23. Carb and nutrient value of onions and their value in the diabetic diet
  24. Carb and nutrient value of onions and their value in the diabetic diet
  25. Accu-Chek Insight insulin pump
  26. Living with diabetes, the diabetic diet, carb counting

Related Issues